Article
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
Blood - 20 Feb 2020
Fournier Elise, Duployez Nicolas, Ducourneau Benoît, Raffoux Emmanuel, Turlure Pascal, Caillot Denis, Thomas Xavier, Marceau-Renaut Alice, Chantepie Sylvain, Malfuson Jean-Valère, Lemasle Emilie, Cheok Meyling, Celli-Lebras Karine, Guerin Estelle, Terré Christine, Lambert Juliette, Pautas Cécile, Dombret Hervé, Castaigne Sylvie, Preudhomme Claude, Boissel Nicolas
Abstract excerpt
Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic background and response to chemotherapy. Although molecular aberrations are routinely used to stratify AML patients into prognostic subgroups when receiving standard chemotherapy, the predictive value of the genetic background and co-occurring mutations remains to be assessed when using newly approved antileukemic drugs. In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.